Список литературы

1. Scully M., Cataland S., Coppo P., et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–22. DOI:10.1111/JTH.13571.

2. Cuker A., Cataland S.R., Coppo P., et al. Redefining Outcomes in Immune TTP: an International Working Group Consensus Report. Blood. 2021;137(14):1855–61. DOI:10.1182/blood.2020009150.

3. Sadler J.E. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130(10):1181–8. DOI:10.1182/BLOOD-2017-04-636431.

4. Hosler G.A., Cusumano A.M., Hutchins G.M. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127(7):834–9. DOI:10.5858/2003-127-834-TTPAHU.

5. Ridolfi R.L., Hutchins G.M., Bell W.R. The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med. 1979;91(3):357–63. DOI:10.7326/0003-4819-91-3-357.

6. Roriz M., Landais M., Desprez J., et al. Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura. Medicine (Baltimore). 2015;94(42):e1598. DOI:10.1097/MD.0000000000001598.

7. van Dorland H.A., Taleghani M.M., Sakai K., et al. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019;104(10):2107–15. DOI:10.3324/HAEMATOL.2019.216796.

8. Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. 2016;54(2):199–202.

9. Moatti-Cohen M., Garrec C., Wolf M., et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888–97. DOI:10.1182/BLOOD-2012-02-408914.

10. Mariotte E., Azoulay E., Galicier L., et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237–45. DOI:10.1016/S2352-3026(16)30018-7.

11. Morgand M., Buffet M., Busson M., et al. High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center. Transfusion. 2014;54(2):389–97. DOI:10.1111/TRF.12263.

12. Wang Z., Yu Z., Su J., et al. Sepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome. Clin Appl Thromb Hemost. 2011;17(3):251–3. DOI:10.1177/1076029609357739.

13. Douglas K.W., Pollock K.G., Young D., et al. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience. J Clin Apher. 2010;25(2):47–53. DOI:10.1002/JCA.20226.

14. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488–94. DOI:10.1038/35097008.

15. Fujimura Y., Matsumoto M., Isonishi A., et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9 Suppl 1(1 S):283–301. DOI:10.1111/J.1538-7836.2011.04341.X.

16. Lotta L.A., Wu H.M., Mackie I.J., et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012;120(2):440–8. DOI:10.1182/BLOOD-2012-01-403113.

17. George J.N. Forecasting the future for patients with hereditary TTP. Blood. 2012;120(2):243–4. DOI:10.1182/BLOOD-2012-05-427419.

18. Page E.E., Kremer Hovinga J.A., Terrell D.R., et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1(10):590–600. DOI:10.1182/BLOODADVANCES.2017005124.

19. Blombery P., Kivivali L., Pepperell D., et al. Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry. Intern Med J. 2016;46(1):71–9. DOI:10.1111/IMJ.12935.

20. Joly B.S., Stepanian A., Leblanc T., et al. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(11):e537–46. DOI:10.1016/S2352-3026(16)30125-9.

21. Amorosi E.L., Ultman J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966;45(3):139–59.

22. Chiasakul T., Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematol Am Soc Hematol Educ Progr. 2018;2018(1):530–8. DOI:10.1182/ASHEDUCATION-2018.1.530.

23. Amalakuhan B., Nambiar A.M. Diagnosis and Management of Thrombotic Thrombocytopenic Purpura. Evidence-Based Crit Care A Case Study Approach. 2017;605–13. DOI:10.1007/978-3-319-43341-7_70.

24. Azoulay E., Bauer P.R., Mariotte E., et al. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med. 2019;45(11):1518–39. DOI:10.1007/S00134-019-05736-5.

25. Benhamou Y., Boelle P.Y., Baudin B., et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost. 2015;13(2):293–302. DOI:10.1111/JTH.12790.

26. Meloni G., Proia A., Antonini G., et al. Thrombotic thrombocytopenic purpura: prospective neurologic, neuroimaging and neurophysiologic evaluation. Haematologica. 2001;86(11):1194–9.

27. Burrus T.M., Wijdicks E.F., Rabinstein A.A. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology. 2009;73(1):66–70. DOI:10.1212/WNL.0B013E3181AAEA1B.

28. Alwan F., Vendramin C., Vanhoorelbeke K., et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):466–71. DOI:10.1182/BLOOD-2016-12-758656.

29. Zafrani L., Mariotte E., Darmon M., et al. Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost. 2015;13(3):380–9. DOI:10.1111/JTH.12826.

30. Wahla A.S., Ruiz J., Noureddine N., et al. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol. 2008;81(4):311–6. DOI:10.1111/J.1600-0609.2008.01112.X.

31. Griffin D., Al-Nouri Z.L., Muthurajah D., et al. First symptoms in patients with thrombotic thrombocytopenic purpura (TTP): what are they and when do they occur? Transfusion. 2013;53(1):235. DOI:10.1111/J.1537-2995.2012.03934.X.

32. Muñiz A.E., Barbee R.W. Thrombotic thrombocytopenic purpura (TTP) presenting as pancreatitis. J Emerg Med. 2003;24(4):407–11. DOI:10.1016/S0736-4679(03)00038-6.

33. Fox L.C., Cohney S.J., Kausman J.Y., et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Intern Med J. 2018;48(6):624–36. DOI:10.1111/IMJ.13804.

34. Scully M., Hunt B.J., Benjamin S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–35. DOI:10.1111/J.1365-2141.2012.09167.X.

35. Aksay E., Kiyan S., Ersel M., et al. Thrombotic thrombocytopenic purpura mimicking acute ischemic stroke. Emerg Med J. 2006;23(9):e51. DOI:10.1136/EMJ.2006.036327.

36. Филатов Л.Б., Томилов А.Ф., Алексеева Т.А. Гемолитическая анемия, вызванная фрагментацией эритроцитов. Клиническая онкогематология. 2011;4(4):346–55.

37. Klein P.J., Pullmann H., Féaux de Lacroix W., et al. Quantitative Bestimmung fragmentierter Erythrocyten (Schistocyten) bei Normalpersonen sowie bei operierten Patienten. Klin Wochenschr. 1975;53(18):847–51. DOI:10.1007/BF01466957.

38. Burns E.R., Lou Y., Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol. 2004;75(1):18–21. DOI:10.1002/AJH.10450.

39. Zini G., D’Onofrio G., Briggs C., et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol. 2012;34(2):107–16. DOI:10.1111/J.1751-553X.2011.01380.X.

40. Uderzo C.C., Jodele S., Eli Missiry M., et al. Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Consensus Based Diagnostic and Therapeutic Recommendations: Which TA-TMA Patients to Treat and When? J Bone Marrow Res. 2014;2(3):10000152. DOI:10.4172/2329-8820.1000152.

41. Gernsheimer T., James A.H., Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121(1):38–47. DOI:10.1182/blood-2012-08-448944.

42. Matsumoto M., Fujimura Y., Wada H., et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol. 2017;106(1):3–15. DOI:10.1007/S12185-017-2264-7.

43. Ayanambakkam A., Kremer Hovinga J.A., Vesely S.K., et al. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. Am J Hematol. 2017;92(11):E644–6. DOI:10.1002/AJH.24885.

44. Thomas M.R., Robinson S., Scully M.A. How we manage thrombotic microangiopathies in pregnancy. Br J Haematol. 2016;173(6):821–30. DOI:10.1111/bjh.14045.

45. Ferrari S., Scheiflinger F., Rieger M., et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007;109(7):2815–22. DOI:10.1182/BLOOD-2006-02-006064.

46. Shelat S.G., Smith P., Ai J., et al. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006;4(8):1707–17. DOI:10.1111/J.1538-7836.2006.02025.X.

47. Sarode R., Bandarenko N., Brecher M.E., et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2014;29(3):148–67. DOI:10.1002/JCA.21302.

48. Knöbl P. Thrombotic thrombocytopenic purpura. Memo. 2018;11(3):220–6. DOI:10.1007/S12254-018-0429-6.

49. Zheng X. Structure-function and regulation of ADAMTS13. J Thromb Haemost. 2013;11(Suppl 1):11–23. DOI:10.1111/jth.12221.

50. Rock G., Anderson D., Clark W., et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol. 2005;129(1):79–86. DOI:10.1111/J.1365-2141.2005.05418.X.

51. Joly B.S., Coppo P., Veyradier A. Pediatric thrombotic thrombocytopenic purpura. Eur J Haematol. 2018;101(4):425–34. DOI:10.1111/ejh.13107.

52. Галстян Г.М., Гапонова Т.В., Шерстнев Ф.С. Клиническое использование криосупернатантной плазмы. Гематология и трансфузилогия. 2020;65(3):351–9.

53. Freedman M., Rock G. Analysis of the products of cryoprecipitation: RiCoF is deficient in cryosupernatant plasma. Transfus Apher Sci. 2010;43(2):179–82. DOI:10.1016/J.TRANSCI.2010.07.004.

54. Picod A., Coppo P. When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP. Transfus Apher Sci. 2019;58(3):273–7. DOI:10.1016/J.TRANSCI.2019.04.012.

55. Zheng X.L., Vesely S.K., Cataland S.R., et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496–502. DOI:10.1111/JTH.15010.